Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

somapacitan

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Innovative Trials has been shortlisted in the PMEA Awards

Innovative Trials finalist in the Support Agency of the Year at the annual PMEA industry awards.

Innovative Trials

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

Pfizer’s proposed $43bn Seagen acquisition unconditionally approved by EC

The transaction is not expected to raise competition concerns or impact treatment prices

- PMLiVE

Pfizer’s pentavalent meningococcal vaccine granted FDA approval

Penbraya helps protect against the five most common meningococcal serogroups

- PMLiVE

FREE Live Webinar – Solving your patient recruitment & retention challenges – 15th November 2023

Join Innovative Trials and Avillion in this FREE webinar

Innovative Trials

- PMLiVE

A New Era in Patient Recruitment & Retention

Innovative Trials launches ‘first of its kind’ service to boost clinical trial patient recruitment and retention .

Innovative Trials

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

Ten ways to start (or continue) your patient engagement journey

Here are 10 easy approaches Pharma teams can take when starting (or continuing) their patient engagement journey!

Impetus Digital

- PMLiVE

Pfizer announces FDA approval for Braftovi/Mektovi combination in lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancers cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links